CRA Insights: A landscape assessment of newborn screening (NBS) in Europe
Newborn screening (NBS) has become an integral part of many public health programs.1 NBS programs have minimized patient suffering which results from extended...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s policy team provides analysis and insights into global, regional and national policy issues affecting patients, the healthcare system, and the life sciences industry. CRA has a reputation for independence and rigor, benefiting from long standing relationships with most leading life sciences organizations as well as national governments and the European Commission and industry associations. Our specialist team has provided unique policy oversight for the past 20 years delivering high quality, robust analysis in a compelling fashion that is accessible to the target audience, whomever it may be.
Newborn screening (NBS) has become an integral part of many public health programs.1 NBS programs have minimized patient suffering which results from extended...
EuropaBio asked Charles River Associates to research the potential impact of the proposed changes included within the EU’s General Pharmaceutical Legislation...
Tim Wilsdon and Antun Sablek present their new study analyzing the expected impact of the GPL on the biotechnology innovation ecosystem. The webinar will...
Five consultants had five posters accepted and one of our consultants presents during a podium session at this year’s event. Myriam Mirza with Merck:...